High-quality dividend stocks are always worth loading up on. This is doubly true for companies that offer shareholders an attractive mix of reliable income and reasonable levels of growth. Nonetheless, this year hasn't been kind to most large-cap dividend stocks. With risk-free assets, like the 10-year Treasury note, offering a near 5% yield, dividend stocks have generally underperformed growth plays in 2023. These two healthcare stocks are proven passive income vehicles...
Pfizer (PFE 1.87%) is going through a rough patch. Slumping sales of its COVID-19 products have caused the drugmaker's shares to plunge by over 40.7% year to date. But it isn't all doom and gloom at the global pharma giant. Johnson & Johnson (JNJ -0.71%) is another deeply undervalued healthcare stock that screens as a top buy for income investors right now. The company's shares have dropped by over 13% year to date in response to litigation concerns, but its underlying business is humming along just fine.
Source: Motley Fool
Related Articles:
________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.